Strides Shasun gets USFDA nod for Abacavir tablets

| | Updated on: Nov 01, 2016

Strides Shasun has received approval from the US health regulator for Abacavir tablets used in the treatment of HIV.

In a BSE filing, Strides Shasun said today: “It has received approval from the United States Food and Drug Administration (USFDA) for Abacavir tablets USP, 300 mg.’’

The product will be manufactured at the company’s USFDA approved facility at Bengaluru and marketed by Strides in the US market.

“The product will be launched immediately,” it added.

According to IMS sales data, the US market for Abacavir is approximately $30 million.

Strides Shasun stock was trading higher by 1.63 per cent at Rs 1,060 on the BSE.

Published on January 15, 2018

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you